Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24391804 | 1.00 | ACHE (0.57) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL24391714 | 0.90 | ENPP1 (0.57) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL22407367 | 0.89 | ENPP1 (0.70) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL31153227 | 0.87 | ENPP1 (0.54) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL24392429 | 0.87 | ENPP1 (0.54) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL24391704 | 0.83 | ACHE (0.58) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL29589572 | 0.83 | ACHE (0.58) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL24391683 | 0.83 | ENPP1 (0.67) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL24391600 | 0.83 | ENPP1 (0.67) | ACHEBACE1ENPP1MAPK1PDGFRB | |
| SCHEMBL29588791 | 0.83 | ENPP1 (0.67) | ACHEBACE1ENPP1MAPK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2024-10-24 | — | — | US | disclosed |
| CN-116848091-A | Inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP 1) and uses thereof | 1CBIO公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4236928-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1Cbio, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | ACHE 208/4885BACE1 947/4885ENPP1 1/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | ACHE 208/4885BACE1 947/4885ENPP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.